Disproportionate reduction of serotonin transporter may predict the response and adherence to antidepressants in patients with major depressive disorder: A positron emission tomography study with 4-[18F]-ADAM

Yi Wei Yeh, Pei Shen Ho, Shin Chang Kuo, Chun Yen Chen, Chih Sung Liang, Che Hung Yen, Chang Chih Huang, Kuo Hsing Ma, Chyng Yann Shiue, Wen Sheng Huang, Jia Fwu Shyu, Fang Jung Wan, Ru Band Lu, San Yuan Huang

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

Background: Many lines of evidence suggest the role of serotonin transporter (SERT)-mediated reuptake of serotonin in the pathophysiology and treatment of major depressive disorder (MDD). This study aimed to examine whether the pretreatment of SERT binding potential or SERT binding ratio between terminal projection regions relative to the midbrain raphe nuclei was associated with treatment outcomes to SERT-targeted antidepressants. Methods: We recruited 39 antidepressant-naïve patients with MDD and 39 heathy controls. Positron emission tomography with N,N-dimethyl-2-(2-amino-4-[18F]fluorophenylthio)benzylamine (4-[18F]-ADAM) was used to measure in vivo SERT availability prior to antidepressant treatment. The 21-item Hamilton Depression Rating Scale (HDRS) was use to assess the severity of depression from baseline to week 6. All the patients with MDD had HDRS scores of 18 or more.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalInternational Journal of Neuropsychopharmacology
Volume18
Issue number7
DOIs
Publication statusPublished - 2015 Jan 1

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Disproportionate reduction of serotonin transporter may predict the response and adherence to antidepressants in patients with major depressive disorder: A positron emission tomography study with 4-[18F]-ADAM'. Together they form a unique fingerprint.

Cite this